Serial #97095713
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

Serial #97095713 Trademark

Serial Number: 97095713 • Registration: 7459467

Serial #97095713 is a trademark filed by TAKEDA PHARMACEUTICAL COMPANY LIMITED on October 27, 2021. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

TAKEDA PHARMACEUTICAL COMPANY LIMITED (367 trademarks)

1-1, DOSHOMACHI 4-CHOME
CHUO-KU, OSAKA , JP

Entity Type: 03

Trademark Details

Filing Date

October 27, 2021

Registration Date

July 30, 2024

Published for Opposition

May 14, 2024

Goods & Services

Pharmaceutical preparations for use in the field of autoimmunology, bacterial infection diseases and disorders, cardiology, central and peripheral nervous systems diseases and disorders, diabetes, endocrinology, haematology, hormonal diseases and disorders, gastroenterology, gout, immunology, infectious diseases and disorders, inflammatory diseases and disorders, musculoskeletal diseases and disorders, neuroscience, oncology, pain management, respiratory diseases and disorders, urological diseases and disorders, viral diseases and disorders, rare diseases namely, autoimmune rare diseases, bacterial infectious rare diseases, cardiological rare diseases, central and peripheral nervous systems rare diseases, diabetes rare diseases, endocrinological rare diseases, haematological rare diseases, hormonally originating rare diseases, gastroenterological rare diseases, gout rare diseases, infectious rare diseases, inflammatory rare diseases, musculoskeletal rare diseases, genetic rare diseases, neurological rare diseases, oncological cancer rare diseases, respiratory rare diseases, urological and kidney rare diseases, viral rare diseases; and pharmaceutical products and preparations containing plasma-derived therapies for treating immunodeficiencies, neuroimmunology, hematology, pulmonology, and rare diseases, namely, autoimmune rare diseases, bacterial infectious rare diseases, cardiological rare diseases, central and peripheral nervous systems rare diseases, diabetes rare diseases, endocrinological rare diseases, haematological rare diseases, hormonally originating rare diseases, gastroenterological rare diseases, gout rare diseases, infectious rare diseases, inflammatory rare diseases, musculoskeletal rare diseases, genetic rare diseases, neurological rare diseases, oncological cancer rare diseases, respiratory rare diseases, urological and kidney rare diseases, viral rare diseases; Pharmaceutical preparations in the field of vaccines, namely, vaccines for human use

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jul 30, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Jul 30, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 14, 2024 NPUB
PUBLISHED FOR OPPOSITION
May 14, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 24, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 10, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 5, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 5, 2024 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Mar 5, 2024 ERFR
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Feb 26, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Feb 26, 2024 XELR
NOTIFICATION OF SUBSEQUENT FINAL EMAILED
Nov 29, 2023 GNS1
SUBSEQUENT FINAL EMAILED
Nov 29, 2023 GNSF
SUBSEQUENT FINAL REFUSAL WRITTEN
Nov 29, 2023 CFRC
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 11, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 10, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 10, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 22, 2023 GNRN
NON-FINAL ACTION E-MAILED
Aug 22, 2023 GNRT
NON-FINAL ACTION WRITTEN
Aug 22, 2023 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 19, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 18, 2023 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jul 18, 2023 ERFR
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Apr 14, 2023 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Apr 14, 2023 XELR
NOTIFICATION OF FINAL REFUSAL EMAILED
Feb 22, 2023 GNFN
FINAL REFUSAL E-MAILED
Feb 22, 2023 GNFR
FINAL REFUSAL WRITTEN
Feb 22, 2023 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 24, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 24, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 24, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 4, 2022 GNRN
NON-FINAL ACTION E-MAILED
Aug 4, 2022 GNRT
NON-FINAL ACTION WRITTEN
Aug 4, 2022 CNRT
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 4, 2022 GNRN
NON-FINAL ACTION E-MAILED
Aug 4, 2022 GNRT
NON-FINAL ACTION WRITTEN
Aug 4, 2022 CNRT
ASSIGNED TO EXAMINER
Aug 4, 2022 DOCK
TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
Nov 12, 2021 TAEA
TEAS VOLUNTARY AMENDMENT RECEIVED
Nov 12, 2021 PARI
NOTICE OF DESIGN SEARCH CODE E-MAILED
Nov 10, 2021 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 9, 2021 NWOS
NEW APPLICATION ENTERED
Oct 30, 2021 NWAP